What medication is recommended for an adult with periodic limb movement disorder (PLMD)?

Treatment of Periodic Limb Movement Disorder (PLMD)

For adults with PLMD, start with gabapentin enacarbil, gabapentin, or pregabalin as first-line therapy, with iron supplementation if ferritin ≤75 ng/mL or transferrin saturation <20%. 1

Primary Pharmacologic Approach

The 2025 American Academy of Sleep Medicine guidelines provide the most current evidence-based framework for treating PLMD, which typically follows the same treatment algorithm as restless legs syndrome (RLS) since PLMD therapy mirrors RLS management 2.

First-Line Medications (Strong Recommendations)

The alpha-2-delta calcium channel ligands are now the mainstay of pharmacologic treatment 3:

• Gabapentin enacarbil - AASM strongly recommends this as first-line therapy (moderate certainty of evidence) 1
• Gabapentin - AASM strongly recommends (moderate certainty of evidence) 1
• Pregabalin - AASM strongly recommends (moderate certainty of evidence) 1

These agents have replaced dopamine agonists as first-line therapy due to accumulating evidence of augmentation (worsening of symptoms) with long-term dopaminergic use 3.

Iron Supplementation Strategy

Check iron studies before initiating any pharmacologic therapy - this is a critical first step that influences all subsequent treatment decisions 1.

Iron Parameters and Treatment Thresholds

For adults with PLMD:

• IV ferric carboxymaltose if ferritin 75-300 ng/mL - AASM strongly recommends (moderate certainty of evidence) 1
• Oral ferrous sulfate OR IV iron if ferritin ≤75 ng/mL or transferrin saturation <20% 1
• IV iron only if ferritin between 75-100 ng/mL 1

Important caveat: Ferric carboxymaltose is more likely to cause hypophosphatemia compared with other IV iron formulations 3. Monitor phosphate levels after administration.

Draw iron studies in the morning after fasting from iron-containing medications and foods for at least 24 hours 1.

Medications to AVOID as Standard Therapy

The 2025 guidelines represent a major shift away from dopaminergic agents:

Conditional Recommendations AGAINST Standard Use:

• Pramipexole - risk of augmentation with long-term use 1
• Ropinirole - risk of augmentation with long-term use 1
• Levodopa - risk of augmentation with long-term use 1
• Transdermal rotigotine - risk of augmentation with long-term use 1

Strong recommendation AGAINST:

• Cabergoline - do not use (risk of heart valve damage) 1

These dopaminergic agents may still be considered for short-term use in patients who prioritize immediate symptom reduction over long-term adverse effects, but they are no longer first-line 1.

Other Medications to Avoid:

• Clonazepam (very low certainty of evidence) 1
• Carbamazepine (low certainty of evidence) 1
• Valproic acid (low certainty of evidence) 1
• Bupropion (moderate certainty of evidence) 1

Alternative and Adjunctive Therapies

Conditional Recommendations FOR Use:

• Extended-release oxycodone and other opioids - conditional recommendation (moderate certainty of evidence) 1. The National RLS Opioid Registry has shown reassuring safety data 3
• Bilateral high-frequency peroneal nerve stimulation - can be used as adjunct therapy in refractory cases (moderate certainty of evidence) 1, 3
• Dipyridamole - conditional recommendation (low certainty of evidence) 1

Clinical Algorithm

1. Obtain iron studies (morning, fasting from iron ≥24 hours)
2. Address exacerbating factors: alcohol, caffeine, antihistamines, serotonergic medications, antidopaminergic medications, untreated sleep apnea 1
3. Iron supplementation based on ferritin/transferrin saturation levels (see above)
4. Start alpha-2-delta ligand: gabapentin enacarbil, gabapentin, or pregabalin
5. If inadequate response: consider opioids or bilateral peroneal nerve stimulation
6. Avoid dopamine agonists as standard therapy due to augmentation risk

Key Pitfalls to Avoid

• Do not use dopamine agonists as first-line therapy - this represents a major paradigm shift from older guidelines 3
• Do not skip iron studies - iron deficiency is implicated in the pathophysiology and treatment can be curative 4
• Do not use cabergoline or pergolide - risk of cardiac valvulopathy 1, 2
• Monitor for augmentation if dopaminergic agents are used - worsening of symptoms, earlier onset, spread to other body parts
• Remember PLMD-specific considerations: PLMD treatment is generally more straightforward than RLS and places greater reliance on addressing the underlying sleep disruption 5